bioMérieux – Third-Quarter 2019 Business Review

• Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year:
  
  • €1,928 million in sales
  • Up 10.3% as reported
• Acceleration of organic growth in sales to reach 9.6% in the third quarter driven bystrong momentum across all Regions
• 2019 targets:
  
  • Organic growth in sales of around 7%
  • Contributive operating income before non-recurring items of between €385 million and €400 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux performed well in the third quarter of 2019. Fast-paced growth continued, driven primarily by a solid increase in reagent sales that reached 8% growth for the first nine months of the year. Given our business outlook and a high basis of comparison in the fourth quarter, organic growth in sales should come in at around 7.0% for the full year and our target margin is confirmed.”